Calendario›GILD›A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA

A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA

Ensayo de GILEAD SCIENCES, INC. en Pre-exposure Prophylaxis for Prevention of HIV Infection (del registro, en inglés).

Fase

no aplica

Estado

Completado

Participantes

64.186

previstos

Centros

1

Fin del objetivo primario

ene 2018

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en abr 2013.

Qué mide

Drug utilization of uninfected individuals who are prescribed FTC/TDF for a PrEP indication, including gaps in therapy (del registro, en inglés) (mes 36)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter information will be used to assess the demographics and other characteristics of the subjects prescribed FTC/TDF or its components in a prospective fashion. The data provider will supply all the de-identified information regarding each visit/interaction that the subject has had with the health system and all the diagnoses and medications that the UI has had prospectively and retrospectively for the length of time captured by the source selected. 200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same source.

Más ensayos de GILD

Todos los de GILD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01865799), actualizada en mar 2018.